This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Santarus' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Stocks in this article: SNTS

In February, we began enrolling patients in our Phase IIIb clinical study to evaluate UCERIS as an add-on therapy to current 5-ASA drugs for the induction of remission of active ulcerative colitis. We expect to complete enrollment in this study in the first half of 2013.

The Phase III clinical study with RHUCIN for the treatment of acute attacks of hereditary angioedema is on track to be completed by the third quarter of this year. As a reminder the successful completion of this study will trigger a $10 million milestone payment to our development partner Pharming.

We are also on schedule with our Phase III clinical study with rifamycin SV MMX for the treatment of travelers’ diarrhea to complete enrollment in the third quarter of this year. And we expect the Phase I clinical study with our anti-VLA-1 antibody SAN-300 to be completed this year.

It’s been just over a year since we had the oral arguments in ZEGERID patent appeal. As we have indicated before the timing of the ruling is entirely at the discretion of the appealing court, but we plan to update shareholders when we receive the ruling.

As part of our ongoing efforts to increase the intellectual property protection on our product portfolio, we’ve recently worked with VeroScience to file a patent application for CYCLOSET under the U.S. PTO’s accelerated process. Under this process, the PTO generally completes its review in one year, and during this time the content of the application are confidential. We recently welcome two new directors to the Santarus board, Alessandro Della Chà and Dr. Matthew Strobeck. Alex is the Senior partner and a co-managing director of a boutique commercial law firm in Milan, Italy, and the director of Cosmo Pharmaceuticals, a key corporate partner.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs